Telomir Pharma’s latest funding round of $3 million through equity financing aims to support its Rare Disease Investigational New Drug (IND) development. Telomir-1, the company’s lead candidate, has shown promising results in preclinical models, including reversing the biological clock, enhancing lifespan and health span, improving mitochondrial energy production, reducing oxidative stress, correcting calcium signaling pathways linked to neurodegeneration, and protecting against metal-induced toxicity. Additionally, Telomir-1 supports cellular regeneration through telomere lengthening and stabilization.
With the successful fundraising, Telomir Pharma is poised to advance its IND program for treating rare diseases. The demonstrated benefits of Telomir-1 in preclinical studies suggest a potential breakthrough in addressing age-related damage and neurodegenerative conditions. This financing round not only provides crucial support for ongoing research and development but also underscores investor confidence in Telomir Pharma’s innovative approach to tackling challenging medical conditions.
Read more from benzinga.com
